Shingrix in Patients With Rheumatic Diseases: a Double-blind Placebo-controlled RCT

Summary

A double-blind randomized controlled trial on the safety and immunogenicity of the recombinant subunit herpes zoster vaccine, Shingrix, in patients with rheumatic diseases undergoing immunosuppressive or biologic/targeted DMARD therapies

Timeline

Start

2026-09-29

Primary completion

2026-09-29

Completion

2026-09-29

Outcome

Outcome not reported

Stopped (Business): “lack of funding”

Drugs

Indications